[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354861-105":59,"doc-detail-354861-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","assessing-the-association-between-homologous-recombination-deficiency-scores-and-treatment-response-in-localized-and-metastatic-prostate-cancer","Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer","","This study evaluates whether homologous recombination deficiency (HRD) scores predict therapeutic efficacy in prostate cancer across localized and metastatic stages under different treatment regimens. Tissue samples from 167 patients underwent genomic sequencing to quantify HRD scores. Sixty-seven localized cases received radical prostatectomy, while 100 metastatic cases received androgen receptor pathway inhibitor therapy. Higher HRD scores corresponded to worse survival and progression-free outcomes, and were linked to increased genomic alterations in genes including BRCA2, CDK12, MYC, and PTEN.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessing-the-association-between-homologous-recombination-deficiency-scores-and-treatment-response-in-localized-and-metastatic-prostate-cancer/354861/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessing-the-association-between-homologous-recombination-deficiency-scores-and-treatment-response-in-localized-and-metastatic-prostate-cancer/354861.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of evaluating HRD scores in this study?","Question",{"text":112,"@type":113},"To assess the predictive value of HRD scores for therapeutic efficacy in prostate cancer across different disease stages and treatment regimens.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were HRD scores measured and in which patient groups were they tested?",{"text":117,"@type":113},"Tissue samples from 167 patients were sequenced to quantify HRD scores; 67 localized patients received radical prostatectomy and 100 metastatic patients received androgen receptor pathway inhibitor treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship did HRD scores show with treatment outcomes?",{"text":121,"@type":113},"Higher HRD scores were associated with notably poorer biochemical progression-free and overall survival after radical prostatectomy, and with reduced progression-free and overall survival outcomes under androgen receptor pathway inhibitor therapy at the metastatic stage.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354861,1790463582,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","The Journal of Pathology: Clinical Research J Pathol Clin Res January 2026; 12: e70069 Published online in Wiley Online Library (wi[leyonlinelibrary.com](leyonlinelibrary.com). DOI: 10.1002/2056-4538.70069)[).](leyonlinelibrary.com). DOI: 10.1002/2056-4538.70069)[ DOI: 10.1002/2056-4538.70069](leyonlinelibrary.com). DOI: 10.1002/2056-4538.70069)  \nORIGINAL ARTICLE  \nAssessing the association between homologous recombination deﬁciency scores and treatment response in localized and metastatic prostate cancer  \nQiyu Zhu 1† , Yifu Shi 1†, Ting Wang2†, Qian Zheng3, Xiuya Zhou4, Zehua Tan 1 , Junru Chen 1 , Jingjing Guo 1 , Haoyang Liu 1 , Pengfei Shen 1 , Hao Zeng 1 * and Jinge Zhao 1 *  \n1 Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, PR China 2Department of Nursing, West China Hospital, Sichuan University, Chengdu, PR China  \n3Department of Respiratory and Critical Care Medicine, Sichuan University, Chengdu, PR China 4Department of Pathology, West China Hospital, Sichuan University, Chengdu, PR China  \n*Correspondence to: Hao Zeng, Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan 610041, [PR China. E-mail:](PR China. E-mail: zengh@scu.edu.cn)[ zengh@scu.edu.cn](PR China. E-mail: zengh@scu.edu.cn), [kucaizeng@163.com](kucaizeng@163.com); Jinge Zhao, Department of Urology, Institute of Urology,  \nWest China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, Sichuan 610041, [PR China. E-mail:](PR China. E-mail: jingezhao@foxmail.com)[ jingezhao@foxmail.com](PR China. E-mail: jingezhao@foxmail.com)  \n†These authors are co-ﬁrst authors and contributed equally.  \nAbstract  \nThe aim of this study was to evaluate the predictive value of homologous recombination deﬁciency scores for therapeutic efﬁcacy in prostate cancer across various disease stages under different regimens. We collected tissue samples from 167 prostate cancer patients and performed genomic sequencing to assess homologous recombination deﬁciency scores. Among them, 67 patients with localized disease received radical prostatectomy, and  \n100 patients with metastatic disease received androgen receptor target inhibitor treatment. We examined the predictive value of homologous recombination deﬁciency scores in forecasting the therapeutic efﬁcacy of standard-of-care treatment of prostate cancer under different disease stages. Among patients who underwent radical prostatectomy, those with higher homologous recombination deﬁciency scores experienced notably shorter biochemical progression-free survival and overall survival than those with lower scores (median biochemical progression-free survival: 50.6 versus 148.4 months, p = 0.037; median overall survival: 149.0 months versus not reached, p = 0.0018). In patients receiving androgen receptor pathway inhibitor treatment, men with higher homologous recombination deﬁciency scores exhibited reduced prostate-speciﬁc antigen progression-free survival, radiographic progression-free survival, and overall survival compared to the lower score group at the metastatic castration-resistant stage (median prostate-speciﬁc antigen progression-free survival: 8.17 versus  \n24.17 months, p = 0.032; median radiographic progression-free survival: 11.8 versus 24.8 months, p = 0.015; median overall survival: 36.5 months versus not reached, p = 0.056) and a deteriorating trend in the metastatic hormone-sensitive stage. Molecular characterization showed that higher homologous recombination deﬁciency scores were associated with higher alteration rates in genes such as BRCA2, CDK12, MYC, and PTEN. This study reveals that higher homologous recombination deﬁciency scores are associated with unfavorable treatment efﬁcacy of radical prostatectomy in localized prostate cancer and of androgen receptor target inhibitor treatment in metastatic prostate cancer.  \nKeywords: HRD scores; prostate cancer; variant; androgen recept","cbCaiknS8ITn4ebl","https://ap.wps.com/l/cbCaiknS8ITn4ebl","pdf",4737140,12,"English","# Abstract\n## Introduction","[{\"question\":\"What was the purpose of evaluating HRD scores in this study?\",\"answer\":\"To assess the predictive value of HRD scores for therapeutic efficacy in prostate cancer across different disease stages and treatment regimens.\"},{\"question\":\"How were HRD scores measured and in which patient groups were they tested?\",\"answer\":\"Tissue samples from 167 patients were sequenced to quantify HRD scores; 67 localized patients received radical prostatectomy and 100 metastatic patients received androgen receptor pathway inhibitor treatment.\"},{\"question\":\"What relationship did HRD scores show with treatment outcomes?\",\"answer\":\"Higher HRD scores were associated with notably poorer biochemical progression-free and overall survival after radical prostatectomy, and with reduced progression-free and overall survival outcomes under androgen receptor pathway inhibitor therapy at the metastatic stage.\"}]","Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer | PDF",1790114476,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6298bf388941cac41fc88ea2e4d5a50b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f785c23d8b01009da04a77e49425b183.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/283fd22224bf8ff2f987263f1ad8c615.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a46455065d59691807d35148251410cb.webp",980,1287]